Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version) Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering Of Units Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version) Jan 07, 2021 Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities Dec 08, 2020 Theratechnologies Announces New Findings For Its Lead Investigational Compound TH1902 For The Treatment Of Several Additional Cancers Nov 23, 2020 Theratechnologies To Present At The Piper Sandler Virtual Healthcare Conference Nov 16, 2020 Theratechnologies Announces Data From Oral Presentation At AASLD Showing How Tesamorelin Can Reduce Fibrosis And NASH Nov 06, 2020 Theratechnologies Announces That Data On The Mechanism Of Effect Of Tesamorelin In NAFLD Will Be Presented At The Liver Meeting® 2020 Nov 03, 2020 Theratechnologies Announces Departure Of Chief Commercial Officer Oct 22, 2020 Theratechnologies To Present At Upcoming Investor Conferences On October 29 And November 10, 2020 First page « Previous page ‹ … Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Page 18 Page 19 Page 20 … Next page › Last page » Displaying 151 - 160 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)
Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)
Jan 07, 2021 Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities
Dec 08, 2020 Theratechnologies Announces New Findings For Its Lead Investigational Compound TH1902 For The Treatment Of Several Additional Cancers
Nov 16, 2020 Theratechnologies Announces Data From Oral Presentation At AASLD Showing How Tesamorelin Can Reduce Fibrosis And NASH
Nov 06, 2020 Theratechnologies Announces That Data On The Mechanism Of Effect Of Tesamorelin In NAFLD Will Be Presented At The Liver Meeting® 2020
Oct 22, 2020 Theratechnologies To Present At Upcoming Investor Conferences On October 29 And November 10, 2020
